halo landing

Article

One click can help millions around the world. Every new healthcare professional who creates a free account on www.cancernetwork.com will trigger our donation of $10 to the international organization Doctors Without Borders/ Mdecins Sans Frontires (MSF) - a non-profit delivering emergency medical assistance in nearly 60 countries to people affected by armed conflict, epidemics, malnutrition, natural disasters, or exclusion from health care. It's our way of promoting global social good for doctors caring for those in desperate need. Our goal is to donate $25,000 - enough for vaccinations for 25,000 people against meningitis, measles, polio or other deadly epidemics.

Imagine that you could
improve the lives of millions
with just a click of a mouse.

You can. And it costs you nothing.

One click can help millions around the world. Every new healthcare professional who creates a free account on www.cancernetwork.com will trigger our donation of $10 to the international organization Doctors Without Borders/ Mdecins Sans Frontires (MSF) - a non-profit delivering emergency medical assistance in nearly 60 countries to people affected by armed conflict, epidemics, malnutrition, natural disasters, or exclusion from health care. It's our way of promoting global social good for doctors caring for those in desperate need. Our goal is to donate $25,000 - enough for vaccinations for 25,000 people against meningitis, measles, polio or other deadly epidemics.

One click improves the care of patients in our local communities.
As a leader in providing highly respected and valued content and services to health care professionals in this country, we provide free content that helps medical practitioners like you become better, more effective and knowledgeable in the latest discoveries. In addition to our donation, your click will grant you access to free, timely content from cancernetwork.com to help keep you on the cutting edge of cancer care.

One click starts the movement - together we can help save lives.

 

Thank you for spreading the word!

 

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content